Cargando…
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis
BACKGROUND: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8...
Autores principales: | Rouvinov, Keren, Levanon, Eran, Peer, Avivit, Sarfaty, Michal, Sarid, David, Neiman, Victoria, Grikshtas, Eduard, Rosenbaum, Eli, Kushnir, Igal, Talmor, Barak, Friger, Michael, Zarbiv, Yonaton, Gez, Eli, Dresler, Hadas, Shalata, Walid, Meirovitz, Amichay, Shrem, Noa Shani, Yakobson, Alexander, Mermershtain, Wilmosh, Keizman, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244774/ https://www.ncbi.nlm.nih.gov/pubmed/37293597 http://dx.doi.org/10.3389/fonc.2023.1151701 |
Ejemplares similares
-
Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
por: Rouvinov, Keren, et al.
Publicado: (2023) -
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study
por: Keizman, Daniel, et al.
Publicado: (2021) -
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study
por: Keizman, Daniel, et al.
Publicado: (2023) -
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
por: Keizman, Daniel, et al.
Publicado: (2016) -
Testicular Metastasis from Renal Cell Carcinoma: A Case Report and Review of the Literature
por: Rouvinov, Keren, et al.
Publicado: (2017)